Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sonnet Biotherapeutics Holdings Inc
(NQ:
SONN
)
0.7100
-0.0200 (-2.74%)
Streaming Delayed Price
Updated: 3:55 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sonnet Biotherapeutics Holdings Inc
< Previous
1
2
3
Next >
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
August 14, 2024
From
Sonnet BioTherapeutics Holdings, Inc.
Via
GlobeNewswire
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
July 24, 2024
From
Sonnet BioTherapeutics Holdings, Inc.
Via
GlobeNewswire
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
June 20, 2024
From
Sonnet BioTherapeutics Holdings, Inc.
Via
GlobeNewswire
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
October 31, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
June 13, 2024
From
Sonnet BioTherapeutics Holdings, Inc.
Via
GlobeNewswire
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
May 28, 2024
From
Sonnet BioTherapeutics Holdings, Inc.
Via
GlobeNewswire
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
May 22, 2024
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
May 20, 2024
Via
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
May 14, 2024
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
May 06, 2024
Via
ACCESSWIRE
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
March 19, 2024
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
March 11, 2024
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
February 29, 2024
Via
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
February 14, 2024
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
December 21, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
December 14, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
October 25, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
October 17, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
September 20, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance
September 19, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split
August 31, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US
August 16, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update
August 14, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference
July 31, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement
June 28, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy
June 23, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab
June 20, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update
May 10, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
April 18, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting
April 17, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.